Inhibition of LEF1-mediated DCLK1 by niclosamide attenuates colorectal cancer stemness

So Yeon Park, Ji Young Kim, Jang Hyun Choi, Jee Heun Kim, Choong Jae Lee, Pomila Singh, Shubhashish Sarkar, Jeong Heum Baek, Jeong Seok Nam

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: Niclosamide, an FDA-approved anthelmintic drug, has been characterized as a potent Wnt inhibitor that can suppress tumor growth and cancer stem-like cell (CSC) populations. However, the underlying molecular mechanisms remain poorly understood. This study aimed to examine how Wnt inhibition by niclosamide preferentially targets CSCs. Experimental Design: The mechanistic role of niclosamide in CSC inhibition was examined in public databases, human colorectal cancer cells, colorectal cancer xenografts, and azox-ymethane/dextran sulfate sodium (AOM/DSS)-induced colorectal cancer model. Results: Niclosamide suppresses CSC populations and their self-renewal activities in colorectal cancer cells, and this CSC-targeting effect leads to irreversible disruption of tumor-initiating potential in vivo. Mechanistically, niclosamide downregulates multiple signaling components of the Wnt pathway, specifically lymphoid enhancer-binding factor 1 (LEF1) expression, which is critical for regulating stemness. Subsequently, we identified that the doublecortin-like kinase 1 (DCLK1)-B is a target of LEF1 and upregulates cancer stemness in colorectal cancer cells. We first documented that niclosamide blocks the transcription of DCLK1-B by interrupting the binding of LEF1 to DCLK1-B promoter. DCLK1-B depletion impairs cancer stemness resulting in reduced survival potential and increased apoptosis, thus sensitizing colorectal cancer to chemoradiation. Conclusions: Disruption of the LEF1/DCLK1-B axis by niclosamide eradicates cancer stemness and elicits therapeutic effects on colorectal cancer initiation, progression, and resistance. These findings provide a preclinical rationale to broaden the clinical evaluation of niclosamide for the treatment of colorectal cancer.

Original languageEnglish (US)
Pages (from-to)1415-1429
Number of pages15
JournalClinical Cancer Research
Volume25
Issue number4
DOIs
StatePublished - Feb 15 2019

Fingerprint

Lymphoid Enhancer-Binding Factor 1
Niclosamide
Colorectal Neoplasms
Phosphotransferases
Neoplastic Stem Cells
Neoplasms
Dextran Sulfate
Wnt Signaling Pathway
Anthelmintics
Therapeutic Uses
Heterografts
Population
Research Design
Up-Regulation
Stem Cells
Down-Regulation
Databases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Inhibition of LEF1-mediated DCLK1 by niclosamide attenuates colorectal cancer stemness. / Park, So Yeon; Kim, Ji Young; Choi, Jang Hyun; Kim, Jee Heun; Lee, Choong Jae; Singh, Pomila; Sarkar, Shubhashish; Baek, Jeong Heum; Nam, Jeong Seok.

In: Clinical Cancer Research, Vol. 25, No. 4, 15.02.2019, p. 1415-1429.

Research output: Contribution to journalArticle

Park, SY, Kim, JY, Choi, JH, Kim, JH, Lee, CJ, Singh, P, Sarkar, S, Baek, JH & Nam, JS 2019, 'Inhibition of LEF1-mediated DCLK1 by niclosamide attenuates colorectal cancer stemness', Clinical Cancer Research, vol. 25, no. 4, pp. 1415-1429. https://doi.org/10.1158/1078-0432.CCR-18-1232
Park, So Yeon ; Kim, Ji Young ; Choi, Jang Hyun ; Kim, Jee Heun ; Lee, Choong Jae ; Singh, Pomila ; Sarkar, Shubhashish ; Baek, Jeong Heum ; Nam, Jeong Seok. / Inhibition of LEF1-mediated DCLK1 by niclosamide attenuates colorectal cancer stemness. In: Clinical Cancer Research. 2019 ; Vol. 25, No. 4. pp. 1415-1429.
@article{79302a3c3e364173ae60010fc2635993,
title = "Inhibition of LEF1-mediated DCLK1 by niclosamide attenuates colorectal cancer stemness",
abstract = "Purpose: Niclosamide, an FDA-approved anthelmintic drug, has been characterized as a potent Wnt inhibitor that can suppress tumor growth and cancer stem-like cell (CSC) populations. However, the underlying molecular mechanisms remain poorly understood. This study aimed to examine how Wnt inhibition by niclosamide preferentially targets CSCs. Experimental Design: The mechanistic role of niclosamide in CSC inhibition was examined in public databases, human colorectal cancer cells, colorectal cancer xenografts, and azox-ymethane/dextran sulfate sodium (AOM/DSS)-induced colorectal cancer model. Results: Niclosamide suppresses CSC populations and their self-renewal activities in colorectal cancer cells, and this CSC-targeting effect leads to irreversible disruption of tumor-initiating potential in vivo. Mechanistically, niclosamide downregulates multiple signaling components of the Wnt pathway, specifically lymphoid enhancer-binding factor 1 (LEF1) expression, which is critical for regulating stemness. Subsequently, we identified that the doublecortin-like kinase 1 (DCLK1)-B is a target of LEF1 and upregulates cancer stemness in colorectal cancer cells. We first documented that niclosamide blocks the transcription of DCLK1-B by interrupting the binding of LEF1 to DCLK1-B promoter. DCLK1-B depletion impairs cancer stemness resulting in reduced survival potential and increased apoptosis, thus sensitizing colorectal cancer to chemoradiation. Conclusions: Disruption of the LEF1/DCLK1-B axis by niclosamide eradicates cancer stemness and elicits therapeutic effects on colorectal cancer initiation, progression, and resistance. These findings provide a preclinical rationale to broaden the clinical evaluation of niclosamide for the treatment of colorectal cancer.",
author = "Park, {So Yeon} and Kim, {Ji Young} and Choi, {Jang Hyun} and Kim, {Jee Heun} and Lee, {Choong Jae} and Pomila Singh and Shubhashish Sarkar and Baek, {Jeong Heum} and Nam, {Jeong Seok}",
year = "2019",
month = "2",
day = "15",
doi = "10.1158/1078-0432.CCR-18-1232",
language = "English (US)",
volume = "25",
pages = "1415--1429",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Inhibition of LEF1-mediated DCLK1 by niclosamide attenuates colorectal cancer stemness

AU - Park, So Yeon

AU - Kim, Ji Young

AU - Choi, Jang Hyun

AU - Kim, Jee Heun

AU - Lee, Choong Jae

AU - Singh, Pomila

AU - Sarkar, Shubhashish

AU - Baek, Jeong Heum

AU - Nam, Jeong Seok

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Purpose: Niclosamide, an FDA-approved anthelmintic drug, has been characterized as a potent Wnt inhibitor that can suppress tumor growth and cancer stem-like cell (CSC) populations. However, the underlying molecular mechanisms remain poorly understood. This study aimed to examine how Wnt inhibition by niclosamide preferentially targets CSCs. Experimental Design: The mechanistic role of niclosamide in CSC inhibition was examined in public databases, human colorectal cancer cells, colorectal cancer xenografts, and azox-ymethane/dextran sulfate sodium (AOM/DSS)-induced colorectal cancer model. Results: Niclosamide suppresses CSC populations and their self-renewal activities in colorectal cancer cells, and this CSC-targeting effect leads to irreversible disruption of tumor-initiating potential in vivo. Mechanistically, niclosamide downregulates multiple signaling components of the Wnt pathway, specifically lymphoid enhancer-binding factor 1 (LEF1) expression, which is critical for regulating stemness. Subsequently, we identified that the doublecortin-like kinase 1 (DCLK1)-B is a target of LEF1 and upregulates cancer stemness in colorectal cancer cells. We first documented that niclosamide blocks the transcription of DCLK1-B by interrupting the binding of LEF1 to DCLK1-B promoter. DCLK1-B depletion impairs cancer stemness resulting in reduced survival potential and increased apoptosis, thus sensitizing colorectal cancer to chemoradiation. Conclusions: Disruption of the LEF1/DCLK1-B axis by niclosamide eradicates cancer stemness and elicits therapeutic effects on colorectal cancer initiation, progression, and resistance. These findings provide a preclinical rationale to broaden the clinical evaluation of niclosamide for the treatment of colorectal cancer.

AB - Purpose: Niclosamide, an FDA-approved anthelmintic drug, has been characterized as a potent Wnt inhibitor that can suppress tumor growth and cancer stem-like cell (CSC) populations. However, the underlying molecular mechanisms remain poorly understood. This study aimed to examine how Wnt inhibition by niclosamide preferentially targets CSCs. Experimental Design: The mechanistic role of niclosamide in CSC inhibition was examined in public databases, human colorectal cancer cells, colorectal cancer xenografts, and azox-ymethane/dextran sulfate sodium (AOM/DSS)-induced colorectal cancer model. Results: Niclosamide suppresses CSC populations and their self-renewal activities in colorectal cancer cells, and this CSC-targeting effect leads to irreversible disruption of tumor-initiating potential in vivo. Mechanistically, niclosamide downregulates multiple signaling components of the Wnt pathway, specifically lymphoid enhancer-binding factor 1 (LEF1) expression, which is critical for regulating stemness. Subsequently, we identified that the doublecortin-like kinase 1 (DCLK1)-B is a target of LEF1 and upregulates cancer stemness in colorectal cancer cells. We first documented that niclosamide blocks the transcription of DCLK1-B by interrupting the binding of LEF1 to DCLK1-B promoter. DCLK1-B depletion impairs cancer stemness resulting in reduced survival potential and increased apoptosis, thus sensitizing colorectal cancer to chemoradiation. Conclusions: Disruption of the LEF1/DCLK1-B axis by niclosamide eradicates cancer stemness and elicits therapeutic effects on colorectal cancer initiation, progression, and resistance. These findings provide a preclinical rationale to broaden the clinical evaluation of niclosamide for the treatment of colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=85061578725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061578725&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-1232

DO - 10.1158/1078-0432.CCR-18-1232

M3 - Article

C2 - 30446587

AN - SCOPUS:85061578725

VL - 25

SP - 1415

EP - 1429

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -